LncRNA MEG3 aggravates acute pulmonary embolism-induced pulmonary arterial hypertension by regulating

Jianfeng Song1, Jinyan Shao1, Shuili Yu1

  • 1Emergency Department, Minhang Hospital, Fudan University, 170 Xinsong Road, Minhang District, Shanghai 201199, PR China.

Insights

Long non-coding RNA MEG3 aggravates acute pulmonary embolism-induced pulmonary hypertension by regulating the miR-34a-3p/DUSP1 pathway. This finding offers a potential new biomarker for pulmonary hypertension treatment.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pulmonary Medicine

Background:

  • Acute pulmonary embolism (APE)-induced pulmonary artery hypertension (PAH) is a critical condition.
  • The miR-34a-3p/DUSP1 pathway plays a role in regulating pulmonary arterial wall thickening and smooth muscle cell proliferation.

Purpose of the Study:

  • To investigate the role of long non-coding RNAs (lncRNAs) in regulating the miR-34a-3p/DUSP1 axis in APE and PAH.
  • To explore MEG3 as a potential regulator in this pathway.

Main Methods:

  • In vitro studies using platelet-derived growth factor-BB (PDGF-BB)-induced human pulmonary arterial smooth muscle cells (hPASMCs).
  • In vivo studies using a rat model of APE.
  • Manipulation of MEG3 and miR-34a-3p levels using overexpression and knockdown techniques.
  • Assessment of cell viability, proliferation, and mean pulmonary arterial pressure (mPAP).

Main Results:

  • MEG3 was found to target miR-34a-3p.
  • MEG3 overexpression exacerbated PDGF-BB-induced hPASMC proliferation and increased mPAP in APE rats.
  • MEG3 influenced the expression of key genes including NOR-1, PCNA, and DUSP1, while downregulating miR-34a-3p.
  • Inhibition of MEG3 (shMEG3) produced opposite effects.
  • MiR-34a-3p mimic reversed MEG3 overexpression effects, and DUSP1 overexpression counteracted MEG3 downregulation effects.

Conclusions:

  • MEG3 aggravates APE-induced PAH by modulating the miR-34a-3p/DUSP1 axis.
  • MEG3 presents potential as a novel biomarker for PAH treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135